Fabrazyme 35 mg

Fabrazyme 35 mg is a powder for solution used for intravenous administration. It contains agalsidase beta, a recombinant enzyme therapy for specific metabolic conditions. This medication is manufactured by Sanofi-Aventis Canada Inc.

Fabrazyme 35 mg is primarily used in the management of certain metabolic disorders. It is designed to help break down specific substances that the body may not process efficiently. Patients often seek this treatment to address symptoms related to enzyme deficiencies, aiming for improved metabolic function.

Common effects of Fabrazyme 35 mg may include reactions at the injection site, such as redness or swelling. Some individuals might experience flu-like symptoms, including fever or chills. These effects vary among users and are not exhaustive.

Fabrazyme 35 mg should be handled with care, following medical guidance. It is crucial to inform healthcare providers about any allergies or existing conditions before use. Proper storage and preparation are essential to maintain the medication's integrity.

Fabrazyme 35 mg may interact with other medications or substances. It is important to discuss all current treatments with a healthcare provider to avoid potential interactions. Always follow professional advice regarding concurrent use with other therapies.